Harold C. Simmons Cancer Center Cancer Cell Networks Scientific Program Project Summary/Abstract The focus of the Cancer Cell Networks Program is to promote investigation that will lead to a mechanistic understanding of aberrant cell regulatory networks supporting tumorigenesis. Approaches range from structural biology to animal models, and much in between. To promote cancer relevance and synergy across Simmons Cancer Center efforts, our scientific goals are broad and remain much the same as in the last submission: Goal 1) Define the mechanisms and pathways that integrate external and internal regulatory cues at the cell autonomous level. Goal 2) Establish how aberrant cell regulatory behavior contributes to cell transformation and tumorigenesis. Goal 3) Facilitate interactions with translational and clinical scientists to test the therapeutic benefit of modulating cell regulatory components. As of 2012, the Cancer Cell Networks Program is co-led by Melanie Cobb, PhD, and James Brugarolas, MD, PhD. The program has grown; it now has 46 members in 17 departments and centers. Five members are Howard Hughes Medical Institute investigators; five, including the program leader, have been elected to the National Academy of Sciences; and one is a Nobel laureate. The investigators in the CCN Program are currently supported by $33.1 million in peer-reviewed funding with $5.0 million from the NCI and $11 million from the Cancer Prevention and Research Institute of Texas (CPRIT). Through a combination of member recruiting and programmatic interactions, the CCN has had much success in engaging the discovery power of UTSW investigators for the development of new cancer focused research initiatives. Since 2009 the members of the CCN Program have authored a total of 382 publications, with 14% of them being intra-programmatic, 34% being inter-programmatic, and 23% inter-institutional with authors from other NCI-designated cancer centers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA142543-10S3
Application #
10260735
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
2010-08-03
Project End
2021-07-31
Budget Start
2019-08-01
Budget End
2020-07-31
Support Year
10
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Type
DUNS #
800771545
City
Dallas
State
TX
Country
United States
Zip Code
75390
Rashdan, Sawsan; Minna, John D; Gerber, David E (2018) Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. Lancet Respir Med 6:472-478
Wijayatunge, Ranjula; Holmstrom, Sam R; Foley, Samantha B et al. (2018) Deficiency of the Endocytic Protein Hip1 Leads to Decreased Gdpd3 Expression, Low Phosphocholine, and Kypholordosis. Mol Cell Biol 38:
Hamann, Heidi A; Shen, Megan J; Thomas, Anna J et al. (2018) Development and Preliminary Psychometric Evaluation of a Patient-Reported Outcome Measure for Lung Cancer Stigma: The Lung Cancer Stigma Inventory (LCSI). Stigma Health 3:195-203
Miyata, Naoteru; Morris, Lindsey L; Chen, Qing et al. (2018) Microbial Sensing by Intestinal Myeloid Cells Controls Carcinogenesis and Epithelial Differentiation. Cell Rep 24:2342-2355
Mokdad, Ali A; Xie, Xian-Jin; Zhu, Hong et al. (2018) Statistical justification of expansion cohorts in phase 1 cancer trials. Cancer 124:3339-3345
Murphy, Caitlin C; Singal, Amit G; Baron, John A et al. (2018) Decrease in Incidence of Young-Onset Colorectal Cancer Before Recent Increase. Gastroenterology 155:1716-1719.e4
Barnes, Arti; Betts, Andrea C; Borton, Eric K et al. (2018) Cervical cancer screening among HIV-infected women in an urban, United States safety-net healthcare system. AIDS 32:1861-1870
Murphy, Caitlin C; Fullington, Hannah M; Alvarez, Carlos A et al. (2018) Polypharmacy and patterns of prescription medication use among cancer survivors. Cancer 124:2850-2857
Zhang, Shuyuan; Nguyen, Liem H; Zhou, Kejin et al. (2018) Knockdown of Anillin Actin Binding Protein Blocks Cytokinesis in Hepatocytes and Reduces Liver Tumor Development in Mice Without Affecting Regeneration. Gastroenterology 154:1421-1434
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29

Showing the most recent 10 out of 501 publications